Cheng, Chialin
Reis, Surya A.
Adams, Emily T.
Fass, Daniel M.
Angus, Steven P.
Stuhlmiller, Timothy J.
Richardson, Jared
Olafson, Hailey
Wang, Eric T.
Patnaik, Debasis
Beauchamp, Roberta L.
Feldman, Danielle A.
Silva, M. Catarina
Sur, Mriganka
Johnson, Gary L.
Ramesh, Vijaya
Miller, Bruce L.
Temple, Sally
Kosik, Kenneth S.
Dickerson, Bradford C.
Haggarty, Stephen J.
Funding for this research was provided by:
NIH (R21NS085487)
Tau Consortium
Marigold Foundation
F-Prime Biomedical Research Initiative
Massachusetts Life Sciences Center Novel Therapeutics Delivery Program
Stuart & Suzanne Steele MGH Research Scholars Program
Massachusetts Center for Alzheimer’s Therapeutic Science/Massachusetts Life Sciences Center
Article History
Received: 6 May 2021
Accepted: 5 August 2021
First Online: 23 August 2021
Competing interests
: The authors declare no competing interests. S.J.H. was or is a member of the scientific advisory board and equity holder in Rodin Therapeutics, Psy Therapeutics, Frequency Therapeutics, Vesigen Therapeutics, and has received speaking or consulting fees from AstraZeneca, Amgen, Merck, Biogen, Syros Pharmaceuticals, Regenacy Pharmaceuticals. S.J.H.’s laboratory has received sponsored research funding from the Tau Consortium, F-Prime Biomedical Research Initiative, AstraZeneca, JW Pharmaceuticals, ATAI, and Stealth BioTherapeutics.